Michael H. Davidson to Disease-Free Survival
This is a "connection" page, showing publications Michael H. Davidson has written about Disease-Free Survival.
Connection Strength
0.124
-
Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-13-S2-16.
Score: 0.030
-
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996 Oct; 23(5 Suppl 12):40-7.
Score: 0.029
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 04; 334(1):1-6.
Score: 0.028
-
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol. 2016 Feb; 77(2):375-83.
Score: 0.028
-
Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant. 1999 Dec; 24(12):1291-7.
Score: 0.009